How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent

CME Available: https://auau.auanet.org/node/41124

At the conclusion of this activity, participants will be able to:

1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.

2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.

3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.

4. Identify patients with radiorecurrent organ-confined prostate cancer.

5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.